Back to Results
First PageMeta Content
Tafamidis / Transthyretin / Biology / Amyloid cardiomyopathy / Clinical trials / Amyloidosis / ClinicalTrials.gov / Familial amyloid cardiomyopathy / Transthyretin-related hereditary amyloidosis / Health / Cardiomyopathy / Medicine


TTR-CM Phase 3 Study Fact Sheet Page 1 of 2 ATTR-ACT: Transthyretin Amyloid Cardiomyopathy Tafamidis Study A Phase 3 Clinical Study in Transthyretin Cardiomyopathy (TTR-CM)
Add to Reading List

Document Date: 2014-04-18 19:15:57

Open Document

File Size: 160,51 KB

Share Result on Facebook

City

Ann Arbor / Philadelphia / Rochester / Cleveland / Baltimore / New York / Chicago / /

Company

Pfizer Inc. / /

Continent

North America / South America / /

Country

Japan / United States / /

Event

FDA Phase / /

MedicalCondition

IV heart failure / Transthyretin Cardiomyopathy / Kansas City Cardiomyopathy Questionnaire Overall Score / amyloidosis / tetramer dissociation / heart failure / /

Organization

New York Heart Association / European Union / Stanford / /

/

Position

physician / /

Product

tafamidis / /

ProvinceOrState

Ohio / Minnesota / Pennsylvania / Maryland / Illinois / New York / Michigan / /

Technology

transplantation / genotype / /

URL

http /

SocialTag